Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > Final Copy Published
View:
Comment by prophetoffactz on Sep 12, 2024 1:25pm
In addition to the potential to treat fibrotic diseases there's a lot in that article with potential significant implications for PGX-YBG as an immune booster, and as a potential bioactive carrier and potential Trojan Horse(M2-like macrophages). This could help with a PGX-YBG/Avenanthramide for cardiovascular disease, etc.  Next do we get the first human avenanthramide pill data and ...more  
Comment by prophetoffactz on Sep 12, 2024 1:54pm
Could have implications for a wound healing franchise. Ai can hallucinate but here's one take: Enhanced Macrophage Uptake The integration of avenanthramides into YBG could leverage the enhanced phagocytic activity observed in M2-like macrophages. These macrophages are associated with tissue repair and anti-inflammatory responses, making them ideal targets for delivering therapeutic agents. ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities